MA44764B1 - Méthodes de traitement de patients présentant une hypercholestérolémie familiale - Google Patents
Méthodes de traitement de patients présentant une hypercholestérolémie familialeInfo
- Publication number
- MA44764B1 MA44764B1 MA44764A MA44764A MA44764B1 MA 44764 B1 MA44764 B1 MA 44764B1 MA 44764 A MA44764 A MA 44764A MA 44764 A MA44764 A MA 44764A MA 44764 B1 MA44764 B1 MA 44764B1
- Authority
- MA
- Morocco
- Prior art keywords
- statin
- lipid
- lowering agent
- methods
- agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention concerne des méthodes de traitement de patients souffrant d'hypercholestérolémie familiale, y compris une HeFH et une HoFH. Les méthodes de l'invention permettent d'abaisser au moins un paramètre lipidique chez le patient par administration d'une quantité thérapeutiquement efficace d'un anticorps ou d'un fragment de liaison à l'antigène de ce dernier qui se lie spécifiquement à ANGPTL3 en combinaison avec une quantité thérapeutiquement efficace d'une statine, un premier agent d'abaissement de lipide autre qu'une statine, et un second agent d'abaissement de lipide autre qu'une statine. Le premier agent d'abaissement de lipide non-statine est un agent qui inhibe l'absorption du cholestérol (par exemple, l'ézétimibe) et le second agent d'abaissement de lipide non-statine est un inhibiteur de la protéine de transfert de triglycéride microsomale (par exemple, le lomitapide). La polythérapie est utile dans le traitement de l'hypercholestérolémie, ainsi que de l'hyperlipidémie, de l'hyperlipoprotéinémie et d'une dyslipidémie, y compris l'hypertriglycéridémie, la chylomicronémie, et pour prévenir ou traiter des maladies ou des troubles, pour lesquels le métabolisme anormal des lipides est un facteur de risque, tels que des maladies cardiovasculaires.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662328823P | 2016-04-28 | 2016-04-28 | |
| US201662348001P | 2016-06-09 | 2016-06-09 | |
| US201762451310P | 2017-01-27 | 2017-01-27 | |
| PCT/US2017/029782 WO2017189813A1 (fr) | 2016-04-28 | 2017-04-27 | Méthodes de traitement de patients présentant une hypercholestérolémie familiale |
| EP17722604.0A EP3448426B1 (fr) | 2016-04-28 | 2017-04-27 | Méthodes de traitement de patients présentant une hypercholestérolémie familiale |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA44764A MA44764A (fr) | 2019-03-06 |
| MA44764B1 true MA44764B1 (fr) | 2025-09-30 |
Family
ID=58692626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA44764A MA44764B1 (fr) | 2016-04-28 | 2017-04-27 | Méthodes de traitement de patients présentant une hypercholestérolémie familiale |
Country Status (24)
| Country | Link |
|---|---|
| US (4) | US20170312359A1 (fr) |
| EP (1) | EP3448426B1 (fr) |
| JP (2) | JP7201437B2 (fr) |
| KR (3) | KR20220148299A (fr) |
| CN (1) | CN109069641A (fr) |
| AU (1) | AU2017258105B2 (fr) |
| CA (1) | CA3021884A1 (fr) |
| DK (1) | DK3448426T3 (fr) |
| ES (1) | ES3032667T3 (fr) |
| FI (1) | FI3448426T3 (fr) |
| HR (1) | HRP20250797T1 (fr) |
| HU (1) | HUE071912T2 (fr) |
| IL (2) | IL262591B (fr) |
| LT (1) | LT3448426T (fr) |
| MA (1) | MA44764B1 (fr) |
| MD (1) | MD3448426T2 (fr) |
| MX (1) | MX2018012741A (fr) |
| PL (1) | PL3448426T3 (fr) |
| PT (1) | PT3448426T (fr) |
| RS (1) | RS66975B1 (fr) |
| SI (1) | SI3448426T1 (fr) |
| SM (1) | SMT202500230T1 (fr) |
| WO (1) | WO2017189813A1 (fr) |
| ZA (1) | ZA201806557B (fr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| MX2018010401A (es) | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
| CN118236391A (zh) | 2017-12-01 | 2024-06-25 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7261494B2 (ja) | 2017-12-01 | 2023-04-20 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用 |
| US11660347B2 (en) | 2017-12-01 | 2023-05-30 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, composition and conjugate containing same, preparation method, and use thereof |
| WO2019105435A1 (fr) | 2017-12-01 | 2019-06-06 | 苏州瑞博生物技术有限公司 | Acide nucléique, composition et conjugué contenant un acide nucléique, procédé de préparation et utilisation |
| CN110997919B (zh) | 2017-12-01 | 2024-04-02 | 苏州瑞博生物技术股份有限公司 | 双链寡核苷酸、含双链寡核苷酸的组合物与缀合物及制备方法和用途 |
| CN110959011B (zh) | 2017-12-29 | 2023-03-28 | 苏州瑞博生物技术股份有限公司 | 缀合物及其制备方法和用途 |
| EP3842534A4 (fr) | 2018-08-21 | 2022-07-06 | Suzhou Ribo Life Science Co., Ltd. | Acide nucléique, composition et conjugué contenant un acide nucléique et leur procédé d'utilisation |
| EP3862024A4 (fr) | 2018-09-30 | 2022-08-17 | Suzhou Ribo Life Science Co., Ltd. | Conjugué d'arn interférent court, son procédé de préparation et utilisation associée |
| CN112423794A (zh) | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| CN112423795A (zh) * | 2018-12-28 | 2021-02-26 | 苏州瑞博生物技术股份有限公司 | 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途 |
| JP7663951B2 (ja) | 2019-05-22 | 2025-04-17 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッド | 核酸、薬物組成物及び複合体ならびに調製方法と使用 |
| AU2020280439B2 (en) | 2019-05-22 | 2025-08-14 | Suzhou Ribo Life Science Co., Ltd. | Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use |
| CN113811613B (zh) | 2019-05-22 | 2024-04-05 | 苏州瑞博生物技术股份有限公司 | 核酸、药物组合物与缀合物及制备方法和用途 |
| US12559551B2 (en) | 2019-05-24 | 2026-02-24 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ANGPTL3 antibodies |
| WO2020238766A1 (fr) | 2019-05-24 | 2020-12-03 | 苏州瑞博生物技术股份有限公司 | Acide nucléique, composition pharmaceutique, conjugué, procédé de préparation et utilisation |
| EP4054625A4 (fr) * | 2019-11-07 | 2026-01-07 | Medimmune Llc | Anticorps de lipase endothéliale pour le traitement de maladies cardiovasculaires |
| WO2021154079A1 (fr) | 2020-01-29 | 2021-08-05 | Rijksuniversiteit Groningen | Moyens et procédés pour moduler le métabolisme lipidique |
| EP4188372A1 (fr) * | 2020-07-29 | 2023-06-07 | Amryt Pharmaceuticals Inc. | Lomitapide destiné à être utilisé dans des méthodes de traitement de l'hyperlipidémie et de l'hypercholestérolémie chez des patients pédiatriques |
| US20220072127A1 (en) * | 2020-08-07 | 2022-03-10 | Regeneron Pharmaceuticals, Inc. | Methods for treating patients with refractory hypercholesterolemia |
| CN112656792B (zh) * | 2021-01-26 | 2022-07-05 | 首都医科大学宣武医院 | 洛美他派在制备用于治疗脑卒中引起的神经损伤药物中的用途 |
| CN119161484A (zh) * | 2022-04-25 | 2024-12-20 | 武汉大学 | 抗asgr1单克隆抗体及其应用 |
| TWI833641B (zh) | 2022-05-02 | 2024-02-21 | 丹麥商諾佛 儂迪克股份有限公司 | 適於高濃度組成物及皮下投藥之新穎抗ａｎｇｐｔｌ３抗體 |
| CN119192369A (zh) * | 2023-06-25 | 2024-12-27 | 百奥泰生物制药股份有限公司 | 抗angptl3抗体及其应用 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US730654A (en) * | 1902-04-17 | 1903-06-09 | John W Hornsey | Hot-air furnace. |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6534088B2 (en) * | 2001-02-22 | 2003-03-18 | Skyepharma Canada Inc. | Fibrate-statin combinations with reduced fed-fasted effects |
| WO2008073300A2 (fr) * | 2006-12-08 | 2008-06-19 | Lexicon Pharmaceuticals, Inc. | Anticorps monoclonaux dirigés contre angptl3 |
| US20130064834A1 (en) * | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
| EP2216016A1 (fr) * | 2009-02-06 | 2010-08-11 | LEK Pharmaceuticals d.d. | Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe |
| CN111700901A (zh) * | 2010-01-08 | 2020-09-25 | Ionis制药公司 | 血管生成素样3表达的调节 |
| WO2012168491A1 (fr) | 2011-06-10 | 2012-12-13 | Novartis Ag | Formulations pharmaceutiques d'antagonistes de pcsk9 |
| JO3412B1 (ar) * | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
| AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
| EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
| WO2015077154A1 (fr) * | 2013-11-20 | 2015-05-28 | Cymabay Therapeutics, Inc. | Traitement de l'hypercholestérolémie familiale homozygote |
| HUE052243T2 (hu) * | 2013-12-24 | 2021-04-28 | Ionis Pharmaceuticals Inc | Az angiopoietin-szerû 3 expressziójának modulációja |
| MX382230B (es) * | 2014-05-01 | 2025-03-13 | Ionis Pharmaceuticals Inc | Composiciones y metodos para modular la expresion de similar a la angiopoyetina tipo 3. |
| MX2018010401A (es) * | 2016-03-03 | 2019-03-06 | Regeneron Pharma | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. |
| PL3439689T3 (pl) * | 2016-04-08 | 2022-01-31 | Regeneron Pharmaceuticals, Inc. | Sposoby leczenia hiperlipidemii inhibitorem angptl8 i inhibitorem angptl3 |
-
2017
- 2017-04-27 AU AU2017258105A patent/AU2017258105B2/en active Active
- 2017-04-27 KR KR1020227036013A patent/KR20220148299A/ko not_active Ceased
- 2017-04-27 IL IL262591A patent/IL262591B/en unknown
- 2017-04-27 ES ES17722604T patent/ES3032667T3/es active Active
- 2017-04-27 RS RS20250643A patent/RS66975B1/sr unknown
- 2017-04-27 CN CN201780026147.XA patent/CN109069641A/zh active Pending
- 2017-04-27 SI SI201731609T patent/SI3448426T1/sl unknown
- 2017-04-27 KR KR1020247003356A patent/KR20240019856A/ko active Pending
- 2017-04-27 SM SM20250230T patent/SMT202500230T1/it unknown
- 2017-04-27 LT LTEPPCT/US2017/029782T patent/LT3448426T/lt unknown
- 2017-04-27 IL IL293308A patent/IL293308B2/en unknown
- 2017-04-27 DK DK17722604.0T patent/DK3448426T3/da active
- 2017-04-27 MA MA44764A patent/MA44764B1/fr unknown
- 2017-04-27 KR KR1020187034616A patent/KR20190003679A/ko not_active Ceased
- 2017-04-27 MX MX2018012741A patent/MX2018012741A/es unknown
- 2017-04-27 MD MDE20190270T patent/MD3448426T2/ro unknown
- 2017-04-27 PT PT177226040T patent/PT3448426T/pt unknown
- 2017-04-27 CA CA3021884A patent/CA3021884A1/fr active Pending
- 2017-04-27 FI FIEP17722604.0T patent/FI3448426T3/fi active
- 2017-04-27 JP JP2018556273A patent/JP7201437B2/ja active Active
- 2017-04-27 HR HRP20250797TT patent/HRP20250797T1/hr unknown
- 2017-04-27 HU HUE17722604A patent/HUE071912T2/hu unknown
- 2017-04-27 PL PL17722604.0T patent/PL3448426T3/pl unknown
- 2017-04-27 US US15/498,687 patent/US20170312359A1/en not_active Abandoned
- 2017-04-27 WO PCT/US2017/029782 patent/WO2017189813A1/fr not_active Ceased
- 2017-04-27 EP EP17722604.0A patent/EP3448426B1/fr active Active
-
2018
- 2018-10-03 ZA ZA2018/06557A patent/ZA201806557B/en unknown
-
2019
- 2019-11-07 US US16/677,319 patent/US20200061189A1/en not_active Abandoned
-
2022
- 2022-07-07 US US17/859,996 patent/US20230000976A1/en not_active Abandoned
- 2022-09-14 JP JP2022145714A patent/JP7404471B2/ja active Active
-
2025
- 2025-07-14 US US19/268,651 patent/US20250332254A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017258105A1 (en) | Methods for treating patients with familial hypercholesterolemia | |
| MX386832B (es) | Inhibidor angptl8 e inhibidor angptl3 para usarse en el tratamiento de hiperlipidemia. | |
| EA201691847A1 (ru) | Способы снижения сердечно-сосудистого риска | |
| MX2018010401A (es) | Metodos para el tratamiento de pacientes con hiperlipidemia administrando un inhibidor de pcsk9 en combinacion con un inhibidor de angptl3. | |
| SG195165A1 (en) | Anti-angptl3 antibodies and uses thereof | |
| MX2021000898A (es) | Inhibidores de pcsk9 para usarse en el tratamiento de pacientes con hipercolesterolemia familiar heterocigota (hfhe). | |
| EA202090510A1 (ru) | Способ лечения бокового амиотрофического склероза придопидином | |
| MX2012007460A (es) | Anticuerpos humanos para proteina 4 de tipo angiopoyetina humana. | |
| MX2023001481A (es) | Metodos para tratar pacientes con hipercolesterolemia refractaria. | |
| EA201590655A8 (ru) | Комбинация лахинимода и придопидина для лечения нейродегенеративных нарушений | |
| MA40240A (fr) | Composés hétéroaryle d'inhibition de la kinase | |
| BR112018014222A2 (pt) | método de tratamento da glomerulopatia c3 | |
| UA102775C2 (uk) | Спосіб лікування болю із застосуванням анти-ngf антитіла | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| NZ703940A (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
| EA201590654A1 (ru) | Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона | |
| EA201891853A1 (ru) | Способы лечения или предотвращения атеросклероза путем введения ингибитора angptl3 | |
| EA201890519A1 (ru) | Ингибирующие антитела против pcsk9 для лечения пациентов с гиперлипидемией, подвергающихся аферезу липопротеинов | |
| JOP20220322A1 (ar) | مثبطات pcsk9 وطرق استخدامها لعلاج الاضطرابات المرتبطة بالكوليسترول | |
| NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| EA201690284A1 (ru) | Композиции и терапевтические способы для ускоренного регресса бляшки | |
| PH12022551052A1 (en) | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor | |
| BR112015019564A2 (pt) | tratamento de esclerose múltipla com laquinimod | |
| NO20093536L (no) | Kombinasjonsterapi ved kreftbehandling som omfatter vinflunin og trastuzumab | |
| MX2023003723A (es) | Anticuerpos anti-il-36r para el tratamiento de dolor inflamatorio cronico. |